Eye docs confront Genentech exec

Put a Genentech executive and a bunch of angry ophthalmologists in the same room, and what do you get? Fireworks. At a conference over the weekend, the company's president of product development, Susan Desmond-Hellman, defended its decision to stop selling Avastin to compounding pharmacies, which repackage the drug for use against macular degeneration.

Desmond-Hellman blamed the move on the FDA, saying, "[w]e had no choice." The FDA's worries about repackaging the cancer med could "put our entire manufacturing operation at risk." That's funny, the eye docs responded. The FDA told us different.

Genentech believes eye docs will still be able to get Avastin for their WMD patients. And Desmond-Hellman vigorously denied that the move was meant to steer patients toward the company's designated WMD drug Lucentis, which runs $2,000 a dose compared with $40 for Avastin.

- read the release from the American Academy of Ophthalmology
- see this the item and from the Wall Street Journal's Health Blog
- read the report from OSN SuperSite

Related Articles:
Genentech rethinks Avastin limits. Report
Why should Medicare pay for Lucentis? Report
Genentech cuts eye docs out of Avastin. Report
Doctors balancing effects, costs of Lucentis and Avastin. Report
Lucentis gets the green light from regulators. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.